Zoster Vaccine (Shingrix)

A recombinant subunit adjuvanted vaccine (RZV) offering strong and lasting protection against herpes zoster (shingles) and its painful complication postherpetic neuralgia. Highly recommended for adults ≥50 years.

The Zoster Vaccine (Shingrix) is recommended for 50 years and above; 19+ years if immunocompromised. It falls under the Adult vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The Zoster Vaccine (Shingrix) has an efficacy of 91–97%. This means it provides significant protection against Herpes Zoster (Shingles) and Postherpetic Neuralgia. Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Pain; redness; swelling at injection site; myalgia. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The Zoster Vaccine (Shingrix) should be avoided by: Severe allergy to a previous shingles vaccine dose; current active shingles episode. Always inform your healthcare provider of your full medical history before vaccination.

The Zoster Vaccine (Shingrix) typically costs ₹8,000 – ₹15,000 in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.